Hypersensitivity to the active substance or to any of the excipients.
Clinically significant active bleeding.
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenousmalformations, vascular aneurysms or major intraspinal or intracerebral vascularabnormalities.
Concomitant treatment with any other anticoagulant agent, e.g., unfractionated heparin (UFH),low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives(fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except underspecific circumstances of switching anticoagulant therapy (see Dosage & Administration) or when UFH isgiven at doses necessary to maintain an open central venous or arterial catheter (see Interactions).